Epoch 26: Innovative Trial Designs for Auto-Immune & Inflammatory Diseases

Early Signals of Efficacy, Umbrella Studies, Basket Studies

Welcome to the 68 NEW Biotech Innovators who have joined us this month! If you haven’t subscribed, join the 1,906 researchers, investors, operators, academics, clinicians and entrepreneurs by subscribing here:

Hello Avatar! Welcome back for another week of biotech analysis. Today is Sunday, which means this is our Building Biotech newsletter that is focused on discussing biopharma strategy topics. Today we are going to focus on clinical trial design. Specifically, with focus on the red hot area of auto-immune disease. If you have been reading our updates you are likely aware that one of the hottest areas in therapeutic development is in auto-immunity. A handful of approaches have recently surfaced which appear to hold promise. These include, FcRNs to deplete auto-antibodies and CAR-T / Bifunctional approaches to B-cell depletion. Given that these mechanisms have potential to show efficacy across a range of different diseases it is not surprising that companies are looking to move quickly to broaden their clinical development programs and explore multiple indications in parallel. Pfizer recently published a paper with a few case studies around how they are going about which we found quite interesting. Particularly as they share some of the thinking we often we often see applied to Oncology clinical development, but here repurposed in the auto-immune setting.

If you're not subbed yet click the link below.  Every Thursday we are out with our FREE public/private biotech market update. Sundays are the days we focus on forward looking strategy.  Monday’s are for public equity research.  Tomorrow we will focus on Pfizer Inc who will shortly share PK data from their much anticipated Phase I study of oral GLP-1 danuglipron for obesity. Options pricing suggest ~10% volatility - not huge compared to our usual updates, but big for a pharma and given the spotlight on this data we figured we would highlight.

Please help spread the work by subscribing and hitting the share button if you are enjoying our newsletters!

Enough shilling for the day, lots to cover this week, let's get started!

INNOVTIVE CLINICAL TRIAL DESIGNS IN INFLAMMATION AND IMMUNOLOGY

The traditional approach to drug development can be a slow and expensive process. Each potential medication undergoes a series of individual trials, one disease at a time. This can be inefficient, especially for complex diseases like those in immunology and inflammation.  Fortunately, there's a new approach: master protocols. These innovative designs allow clinicians to evaluate multiple drugs or patient groups within a single study. This can significantly reduce costs and expedite the development of new treatments.